Gateway Biotechnology, Inc.

Close-up of the top of the Saint Louis Gateway Arch with blue skies and some clouds in the background. Gateway Biotechnology.

Founding Story

Gateway stems from a collaboration between doctors at Washington University in St. Louis (WUSTL). After screening FDA-approved drugs in 2006 and discovering a family of drugs that can be used against hearing loss, Drs. Bao, Chole, and Perez formed Gateway Biotechnology, Inc. in 2011 to help transition their preclinical findings into medical interventions against hearing loss.

​Gateway focuses on drug repurposing for hearing disorders by identifying promising drug combinations or drugs not yet available in the United States. By working with academic institutions and pharmaceutical companies, we have developed functional technology platforms to validate the safety, efficacy, and quality of our product lines.

Playing chess. Gateway Biotechnology.

Leadership Team

Jianxin Bao, Ph.D

Co-founder, President

Dr. Bao has studied the hearing system extensively at Stanford University, Harvard University, Columbia University, University of Florida, and WUSTL. His excellence has been recognized by the National Institute on Aging and the National Institute on Deafness and Other Communication Disorders. Dr. Bao’s pioneering research into the molecular mechanisms of hearing disorders has resulted in multiple NIH awards and provided the scientific foundations for Gateway Biotechnology, Inc.. His experience working with physicians, clinicians, and academic researchers provides a valuable perspective and facilitates the transition from discovery to product development.

Ronald Bassuner, Ph.D., D. Sc.

Director of Business Development

Dr. Bassuner has expertise in biotechnology, project management, and commercialization. His academic career at the Academy of Sciences in Berlin, Germany and his experience with biotechnology companies across the globe allows him to effectively direct business activities for the company. He helps translate innovative scientific principles into economically-feasible products and allows the company to achieve deliverables on time, in quality, and within budget.

Richard A. Chole, M.D., Ph.D.


Dr. Chole is a well-known clinician with a specialty in neurotology and has led multiple research projects at WUSTL. He carried out the first study of age-related hearing loss in the mouse C57BL/6J model and has conducted several clinical trials in the field of hearing disorders.

Philip Perez, M.D.


Dr. Perez studied at Harvard University and the medical school at WUSTL. He was involved in the first drug re-purposing studies to fight hearing loss and is currently practicing medicine at the University of Pittsburg.